ClinicalTrials.gg
CompletedNCT01323374FMS201Updated Feb 14, 2024

Study To Assess The Clinical Benefit Of Droxidopa And Droxidopa/Carbidopa In Subjects With Fibromyalgia

A Phase 2 interventional study of Droxidopa and Carbidopa in Fibromyalgia, sponsored by Chelsea Therapeutics. Completed at 7 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-14.

Sponsored by Chelsea Therapeutics (part of H. Lundbeck A/S) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Fibromyalgia with a site in United Kingdom — 4 open to participants now, 6 under way, none of them phase 3. Fibromyalgia · United Kingdom.

Enrollment
15th of 22
122 · median 266
Started
2009
the only one that year
Phase 2
5 of 31
none open now
Registered
11th of 31
by date

Among the 31 studies in Fibromyalgia with a site in United Kingdom, this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2009, is one of 5 in phase 2, and was the 11th registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

4 of the 31 studies in Fibromyalgia with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Fibromyalgia with a site in United Kingdom, or all of them as a file.
02

Study summary

A correlation between increased norepinephrine concentration in the central nervous system (CNS) and a decrease in fibromyalgia pain has been suggested in clinical studies. Therefore, as a pro-drug of norepinephrine, droxidopa could potentially benefit fibromyalgia patients by reducing pain as a result of increasing CNS levels of norepinephrine.

As this benefit is presumed to be a central effect, the addition of carbidopa, a peripheral DOPA decarboxylase (DDC) inhibitor, may favorably impact the drug's treatment profile. Carbidopa is utilized as a blocker of peripheral DDC, an enzyme required for the conversion of droxidopa into norepinephrine. Therefore, inhibition of peripheral DDC should result in a reduction of any side effects resulting from the peripheral production of norepinephrine, whilst allowing for increased central levels, and hence, increased centrally mediated benefits.

The purpose of the study is the obtain information regarding the proper dosing, effectiveness and safety of droxidopa and combination droxidopa/carbidopa treatments in patients with fibromyalgia.

Read the detailed description

Fibromyalgia syndrome (FMS) and Chronic widespread pain (CWP) are two syndromes within a broader class known as functional somatic syndromes. Chronic widespread pain (CWP) is defined according to the American College of Rheumatology (ACR), as pain both above and below the waist involving both sides of the body and lasting for at least 3 months. Fibromyalgia syndrome (FMS), a subset of CWP, is a multisystem disease characterized by sleep disturbance, fatigue, headache, morning stiffness, paresthesias, and anxiety.

While there is debate as to specific etiology and pathogenesis, fibromyalgia is generally believed to be the result of a perturbation of central pain processing, specifically the neuroendocrine system. Fibromyalgia patients have been shown to have lower levels of metabolites from three neurotransmitters (serotonin, norepinephrine, and dopamine) in their cerebrospinal fluid (CSF) compared to healthy controls. The low rate of turnover of these neurotransmitters supports the hypothesis of a metabolic defect in fibromyalgia and suggests that the defect occurs at a neuroregulatory level. Results of a study that examined the effect of a permanent reduction in the noradrenergic innervation of the spinal cord suggested that the antinociceptive effects of norepinephrine are closely linked to opioidergic and tachykinergic neurotransmission.

Droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies to date, data suggests that droxidopa is well-tolerated and effective as a norepinephrine precursor.

Pre-clinical and clinical studies suggest that droxidopa has an analgesic effect in patients with chronic pain. An increase in central nervous system (CNS) levels of norepinephrine has been shown to correlate with an analgesic effect. Based on the pre-clinical and clinical findings to date, it is hypothesized that droxidopa can provide pain reduction in fibromyalgia patients through increasing the CNS levels of norepinephrine.

Carbidopa is a DOPA decarboxylase (DDC) inhibitor. At therapeutic doses carbidopa does not cross the blood-brain barrier and therefore should not inhibit CNS metabolism of droxidopa to NE. Decreasing the activity of DDC in the periphery enables droxidopa metabolism to be focused in the CNS. This CNS focus should increase CNS response while also limiting the increase in blood pressure associated with peripheral droxidopa metabolism. In addition, as DDC is an enzyme required for the conversion of droxidopa into its active metabolite norepinephrine, inhibition of peripheral DDC, utilizing Carbidopa, should result in a reduction of any side effects resulting from the peripheral production of NE, whilst allowing for increased central levels, and hence, increased centrally mediated benefits.

The primary objective of this study is to determine the efficacy of droxidopa and droxidopa/carbidopa in the treatment of pain associated with fibromyalgia. Secondary objectives include: evaluation of the effect of droxidopa and combinations of droxidopa/carbidopa on signs and symptoms of fibromyalgia, evaluation of the effect of droxidopa and combinations of droxidopa/carbidopa on the overall quality of life of fibromyalgia patients, evaluation of the dose-response relationship for droxidopa between different doses of droxidopa, carbidopa and combinations of droxidopa/carbidopa in fibromyalgia patients, evaluation of the clinical benefit of treatment with different doses of droxidopa, carbidopa and combinations of droxidopa/carbidopa in fibromyalgia patients, estimation of the optimal dose for relief of fibromyalgia pain using response surface methodology, and evaluation of the safety of droxidopa and droxidopa/carbidopa treatments.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Fibromyalgia
  • FMS
  • droxidopa
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female and aged 18 years or over
  • Clinical diagnosis of fibromyalgia as defined by the 1990 American College of Rheumatology (ACR) criteria
  • Provide written to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care
  • Have a score of between 20mm and 90mm on the Visual Analog Scale for Pain (VAS-P) section of the SF-MPQ at screening and baseline visits

Exclusion criteria

Exclusion Criteria:

  • Have uncontrolled hypertension (defined as systolic blood pressure >160 mmHg and/or diastolic blood pressure >110 mmHg) or use of ≥2 antihypertensive medications
  • Patients currently taking pregabalin; unless they provide written and agree to discontinue pregabalin use 3 weeks prior to other screening procedures and for the duration of the study
  • Currently taking tri-cyclic antidepressant medication
  • Currently taking any norepinephrine re-uptake inhibitors
  • Have depression noted as significant by a score greater than 17 on the Hamilton Depression Scale (HAM-D)
  • History of known or suspected drug or substance abuse
  • Women of who are not using a medically accepted (: Female subjects should be either (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential (WOCP) who are using or agree to use acceptable methods of contraception throughout the study period and for 4 weeks after the last dose of product. Acceptable contraceptives include intrauterine devices (IUDs), hormonal contraceptives (oral, depot, patch or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. If hormonal contraceptives are used they should be taken according to the package insert. WOCP who are not currently sexually active must agree to use acceptable contraception, as defined above, if they decide to become sexually active during the period of the study and for 4 weeks after the last dose of investigational product. For WOCP a urine pregnancy test must be conducted at screening, baseline and study termination; the results must be negative at screening and at baseline. Any positive result will be confirmed by serum beta HCG pregnancy test).
  • Sexually active males whose partner is a WOCP must agree to use condoms for the duration of the study and for 4 weeks after the last dose
  • Women who are pregnant, breast feeding, or plan to become pregnant during the course of this study
  • Known or suspected to the study medication or any of its ingredients
  • Have in the investigator's opinion any significant cardiac arrhythmia
  • Any significant systemic, hepatic, cardiac or renal illness
  • Diabetes mellitus or insipidus
  • Have a history of closed angle glaucoma
  • Have a known or suspected current . Patients with a history of cancer must be symptom- and treatment-free for at least 5 years prior to randomization, with the exception of patients with non-melanoma, non-invasive skin cancers (such as basal cell carcinoma), who should not have had an intervention or recurrence within one year of starting the study
  • Patients with known gastrointestinal illness or other gastrointestinal disorder that may, in the investigator's opinion, affect the absorption of study drug
  • In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing
  • In the investigator's opinion, are unable to adequately co-operate because of individual or family situation
  • In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia
  • Are not able or willing to comply with the study requirements for the duration of the study
  • Have participated in another clinical trial with an investigational agent (including named patient or compassionate use protocol) within 1 month before the start of the study
  • Previous enrollment in the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Droxidopa 200mg TID

    Drug: Droxidopa

  • Experimental
    Droxidopa 400mg TID

    Drug: Droxidopa

  • Experimental
    Droxidopa 600mg TID

    Drug: Droxidopa

  • Active comparator
    Carbidopa 25mg TID

    Drug: Carbidopa

  • Active comparator
    Carbidopa 50 mg TID

    Drug: Carbidopa

  • Experimental
    Droxidopa/carbidopa 200mg/25mg TID

    Drug: Droxidopa/carbidopa

  • Experimental
    Droxidopa/carbidopa 400mg/25mg TID

    Drug: Droxidopa/carbidopa

  • Experimental
    Droxidopa/carbidopa 600mg/25mg TID

    Drug: Droxidopa/carbidopa

  • Experimental
    Droxidopa/carbidopa 200mg/50mg TID

    Drug: Droxidopa/carbidopa

  • Experimental
    Droxidopa/carbidopa 400mg/50mg TID

    Drug: Droxidopa/carbidopa

  • Experimental
    Droxidopa/carbidopa 600mg/50mg TID

    Drug: Droxidopa/carbidopa

  • Placebo comparator
    Placebo TID

    Drug: Placebo

Interventions

  • Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.

    Also known as: L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, L-DOPS

  • Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.

    Also known as: Lodosyn

  • DrugDroxidopa/carbidopa

    Drug pages: DroxidopaStudies of DroxidopaDroxidopa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarbidopaStudies of CarbidopaCarbidopa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.

    Also known as: L-threo-3,4-dihydroxyphenylserine / Lodosyn, L-threo-DOPS / Lodosyn, L-DOPS / Lodosyn

  • DrugPlacebo

    Oral, placebo TID

    Also known as: Inactive ingrediant

06

What researchers measure

Primary outcomes

  1. Determine the efficacy of droxidopa and droxidopa/carbidopa in the treatment of pain associated with fibromyalgia

    Time frame: Baseline to end of 8 week treatment period

Secondary outcomes

  1. Evaluate the effect of droxidopa and combinations of droxidopa/carbidopa on signs and symptoms of fibromyalgia (including depression, fatigue, and sleep disorder)

    Time frame: Baseline to end of 8 week treatment period

  2. Evaluate the effect of droxidopa and combinations of droxidopa/carbidopa on the overall quality of life of fibromyalgia patients

    Time frame: Baseline to end of 8 week treatment period

  3. Evaluate the dose-response relationship for droxidopa (200, 400, and 600mg TID), carbidopa (25 and 50mg TID) and combinations of droxidopa/carbidopa (200/25, 200/50, 400/25, 400/50, 600/25 and 600/50mg TID) in the treatment of fibromyalgia patients

    Time frame: Baseline to end of 8 week treatment period

  4. Evaluate the clinical benefit of treatment with 200, 400, and 600mg droxidopa TID, or 25 and 50mg carbidopa TID and combinations of droxidopa/carbidopa 200/25, 200/50, 400/25, 400/50, 600/25 and 600/50mg TID in the treatment of fibromyalgia patients

    Time frame: Baseline to end of 8 week treatment period

  5. Estimate the optimal dose for relief of fibromyalgia pain using response surface methodology

    Time frame: Baseline to end of 8 week treatment period

  6. Evaluate the safety of droxidopa and droxidopa/carbidopa treatments based on the occurrence of treatment-emergent adverse events (AE) and specific evaluation of blood pressure, heart rate, ECG, and laboratory findings across the study.

    Time frame: Baseline to end of 4 week follow-up period following 8 week treatment period

07

Study locations

7 sites
  • Rheumatology Department; Barnsley Hospital NHS Foundation Trust
    Barnsley, S75 2EP, United Kingdom
  • MAC UK Neuroscience
    Liverpool, L18 1HQ, United Kingdom
  • Academic Dept of Rheumatology, Kings College London
    London, SE5 9RJ, United Kingdom
  • MAC UK Neuroscience
    Manchester, M32 0UT, United Kingdom
  • Musculoskeletal Department; Freeman Hospital
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • Rheumatology Department, Poole Hospital NHS Trust
    Poole, BH15 2JB, United Kingdom
  • Clinical Trials Unit; Main Hospital; Salford Rooyal NHS Foundation Trust
    Salford, M6 8HD, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2011
First posted
Mar 25, 2011
Start
Jan 2009
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Feb 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01323374
Responsible party
Sponsor
First posted
Mar 25, 2011
Start date
Jan 2009
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Feb 14, 2024

Study contacts

Ernest Choy, M.D.
principal investigator · Academic Dept of Rheumatology Kings College London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Droxidopa · Carbidopa

Start the discussion